| The regulation and importance of monocyte chemoattractant protein-1 |
23 |
| NOTCH regulation of the endothelial cell phenotype |
18 |
| Clozapine-induced agranulocytosis/granulocytopenia: mechanisms and monitoring |
16 |
| Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors |
12 |
| MicroRNAs in endothelial cell homeostasis and vascular disease |
12 |
| Pathophysiology of immune thrombocytopenia |
12 |
| New insights into the links between hypoxia and iron homeostasis |
10 |
| Mechanisms of failure of chimeric antigen receptor T-cell therapy |
9 |
| Endothelial cell protein C receptor-dependent signaling |
8 |
| Neutropenia in glycogen storage disease Ib: outcomes for patients treated with granulocyte colony-stimulating factor |
8 |
| Rapamycin and treatment of venous malformations |
8 |
| Fibrinogen and factor XIII: newly recognized roles in venous thrombus formation and composition |
8 |
| Multiple protein disulfide isomerases support thrombosis |
8 |
| Tolerance induction in hemophilia: innovation and accomplishments |
7 |
| Progress towards improving homing and engraftment of hematopoietic stem cells for clinical transplantation |
7 |
| Pathogenesis of Neisseria gonorrhoeae in the female reproductive tract: neutrophilic host response, sustained infection, and clinical sequelae |
7 |
| Have haploidentical transplants replaced umbilical cord transplants for acute leukemias? |
7 |
| Resistance in chronic myeloid leukemia: definitions and novel therapeutic agents |
6 |
| Integrative view on how erythropoietin signaling controls transcription patterns in erythroid cells |
6 |
| Microenvironment signaling driving lymphomagenesis |
6 |
| PIK3CA mutations in vascular malformations |
6 |
| p53 involvement in clonal hematopoiesis of indeterminate potential |
6 |
| Altered functions of platelets during aging |
6 |
| The future of cell-free DNA testing to guide therapeutic decisions in B-cell lymphomas |
5 |
| Progress in the problem of relapsed or refractory acute myeloid leukemia |
5 |
| Transfusion support and alternatives for Jehovah's Witness patients |
5 |
| SOX a key oncogenic factor in mantle cell lymphoma |
5 |
| Dysregulated myelopoiesis and hematopoietic function following acute physiologic insult |
5 |
| Neutropenia in Barth syndrome: characteristics, risks, and management |
5 |
| Mechanisms of leukemic transformation in congenital neutropenia |
5 |
| Microtransplantation: clinical applications and mechanisms |
5 |
| Delayed haemolytic and serologic transfusion reactions: pathophysiology, treatment and prevention |
5 |
| Towards increasing shelf life and haemostatic potency of stored platelet concentrates |
5 |
| Hemolysis and immune regulation |
5 |
| Recent insights into vascular development from studies in zebrafish |
4 |
| Outpatient induction and consolidation care strategies in acute myeloid leukemia |
4 |
| Exosomes in acute myeloid leukemia inhibit hematopoiesis |
4 |
| Emerging single-cell tools are primed to reveal functional and molecular heterogeneity in malignant hematopoietic stem cells |
4 |
| Toll-like receptor signaling in hematopoietic stem and progenitor cells |
4 |
| Subverting bradykinin-evoked inflammation by co-opting the contact system: lessons from survival strategies of Trypanosoma cruzi |
4 |
| Emerging applications of aptamers for anticoagulation and hemostasis |
4 |
| The plasma contact system as a modulator of innate immunity |
4 |
| Green neutrophilic inclusions: current understanding and review of literature |
3 |
| Cancer cell-derived tissue factor-positive extracellular vesicles: biomarkers of thrombosis and survival |
3 |
| CD36 and ERK5 link dyslipidemia to apoptotic-like platelet procoagulant function |
3 |
| The most novel of the novel agents for acute myeloid leukemia |
3 |
| New therapeutic strategies for high-risk acute myeloid leukemia |
3 |
| Cohesin mutations in myeloid malignancies made simple |
3 |
| CADASIL: new advances in basic science and clinical perspectives |
3 |
| Pain and sickle cell disease |
3 |
